These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

392 related articles for article (PubMed ID: 32728989)

  • 21. Left atrial function in patients with light chain amyloidosis: A transthoracic 3D speckle tracking imaging study.
    Mohty D; Petitalot V; Magne J; Fadel BM; Boulogne C; Rouabhia D; El Hamel C; Lavergne D; Damy T; Aboyans V; Jaccard A
    J Cardiol; 2018 Apr; 71(4):419-427. PubMed ID: 29153741
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Longitudinal strain of left ventricular basal segments and E/e' ratio differentiate primary cardiac amyloidosis at presentation from hypertensive hypertrophy: an automated function imaging study.
    Schiano-Lomoriello V; Galderisi M; Mele D; Esposito R; Cerciello G; Buonauro A; Della Pepa R; Picardi M; Catalano L; Trimarco B; Pane F
    Echocardiography; 2016 Sep; 33(9):1335-43. PubMed ID: 27277827
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Reduced trans-mitral A-wave velocity predicts the presence of wild-type transthyretin amyloidosis in elderly patients with left ventricular hypertrophy.
    Yamamura S; Izumiya Y; Ishida T; Onoue Y; Kimura Y; Hanatani S; Araki S; Fujisue K; Sueta D; Kanazawa H; Takashio S; Usuku H; Sugamura K; Sakamoto K; Yamamoto E; Yamamuro M; Yasuda H; Kojima S; Kaikita K; Hokimoto S; Ogawa H; Tsujita K
    Heart Vessels; 2017 Jun; 32(6):708-713. PubMed ID: 27882404
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Diagnostic and prognostic value of the left atrial myopathy evaluation in cardiac amyloidosis using echocardiography.
    Ferkh A; Geenty P; Stefani L; Emerson P; Pham J; Byth K; Boyd AC; Richards D; Taylor MS; Kwok F; Kizana E; Thomas L
    ESC Heart Fail; 2024 Dec; 11(6):4139-4147. PubMed ID: 39129371
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Disease progression in cardiac morphology and function in heart failure: ATTR cardiac amyloidosis versus hypertensive left ventricular hypertrophy.
    Henein MY; Pilebro B; Lindqvist P
    Heart Vessels; 2022 Sep; 37(9):1562-1569. PubMed ID: 35275264
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Association of left atrial reservoir function with left atrial structural remodeling related to left ventricular dysfunction in asymptomatic patients with hypertension: evaluation by two-dimensional speckle-tracking echocardiography.
    Miyoshi H; Oishi Y; Mizuguchi Y; Iuchi A; Nagase N; Ara N; Oki T
    Clin Exp Hypertens; 2015; 37(2):155-65. PubMed ID: 25050647
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Differentiation of light-chain cardiac amyloidosis from hypertrophic cardiomyopathy using myocardial mechanical parameters by velocity vector imaging echocardiography.
    Zhang L; Zhou X; Wang J; Mu Y; Liu B; Lv W; Wang Y; Liu H; Liu H; Zhi G
    Int J Cardiovasc Imaging; 2017 Apr; 33(4):499-507. PubMed ID: 27878699
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Noninvasive Mapping of the Electrophysiological Substrate in Cardiac Amyloidosis and Its Relationship to Structural Abnormalities.
    Orini M; Graham AJ; Martinez-Naharro A; Andrews CM; de Marvao A; Statton B; Cook SA; O'Regan DP; Hawkins PN; Rudy Y; Fontana M; Lambiase PD
    J Am Heart Assoc; 2019 Sep; 8(18):e012097. PubMed ID: 31496332
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prognostic value of left atrial function in systemic light-chain amyloidosis: a cardiac magnetic resonance study.
    Mohty D; Boulogne C; Magne J; Varroud-Vial N; Martin S; Ettaif H; Fadel BM; Bridoux F; Aboyans V; Damy T; Jaccard A
    Eur Heart J Cardiovasc Imaging; 2016 Sep; 17(9):961-9. PubMed ID: 27194782
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Diffusion Tensor Cardiovascular Magnetic Resonance in Cardiac Amyloidosis.
    Khalique Z; Ferreira PF; Scott AD; Nielles-Vallespin S; Martinez-Naharro A; Fontana M; Hawkins P; Firmin DN; Pennell DJ
    Circ Cardiovasc Imaging; 2020 May; 13(5):e009901. PubMed ID: 32408830
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Differentiation of hypertrophic cardiomyopathy and cardiac amyloidosis from other causes of ventricular wall thickening by two-dimensional strain imaging echocardiography.
    Sun JP; Stewart WJ; Yang XS; Donnell RO; Leon AR; Felner JM; Thomas JD; Merlino JD
    Am J Cardiol; 2009 Feb; 103(3):411-5. PubMed ID: 19166699
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Characteristics of Left Atrial Deformation Parameters and Their Prognostic Impact in Patients with Pathological Left Ventricular Hypertrophy: Analysis by Speckle Tracking Echocardiography.
    Iio C; Inoue K; Nishimura K; Fujii A; Nagai T; Suzuki J; Okura T; Higaki J; Ogimoto A
    Echocardiography; 2015 Dec; 32(12):1821-30. PubMed ID: 25959698
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Left atrial myocardial function in either physiological or pathological left ventricular hypertrophy: a two-dimensional speckle strain study.
    D'Andrea A; De Corato G; Scarafile R; Romano S; Reigler L; Mita C; Allocca F; Limongelli G; Gigantino G; Liccardo B; Cuomo S; Tagliamonte G; Caso P; Calbrò R
    Br J Sports Med; 2008 Aug; 42(8):696-702. PubMed ID: 18070810
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cardiac Amyloidosis: Mimics, Multimodality Imaging Diagnosis, and Treatment.
    Fazlinezhad A; Naqvi TZ
    JACC Cardiovasc Imaging; 2020 Jun; 13(6):1384-1391. PubMed ID: 32061555
    [No Abstract]   [Full Text] [Related]  

  • 35. Effects of tafamidis on the left ventricular and left atrial strain in patients with wild-type transthyretin cardiac amyloidosis.
    Nishizawa RH; Kawano H; Yoshimuta T; Eguchi C; Kojima S; Minami T; Sato D; Eguchi M; Okano S; Ikeda S; Ueda M; Maemura K
    Eur Heart J Cardiovasc Imaging; 2024 Apr; 25(5):678-686. PubMed ID: 38109497
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Potential clinical relevance of cardiac magnetic resonance to diagnose cardiac light chain amyloidosis.
    Dohy Z; Szabo L; Pozsonyi Z; Csecs I; Toth A; Suhai FI; Czimbalmos C; Szucs A; Kiss AR; Becker D; Merkely B; Vago H
    PLoS One; 2022; 17(6):e0269807. PubMed ID: 35696411
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Parametric mapping using cardiovascular magnetic resonance for the differentiation of light chain amyloidosis and transthyretin-related amyloidosis.
    Kravchenko D; Isaak A; Zimmer S; Öztürk C; Mesropyan N; Bischoff LM; Voigt M; Ginzburg D; Attenberger U; Pieper CC; Kuetting D; Luetkens JA
    Eur Heart J Cardiovasc Imaging; 2024 Sep; 25(10):1451-1461. PubMed ID: 38912832
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hypertensive patients with left ventricular hypertrophy have global left atrial dysfunction and impaired atrio-ventricular coupling.
    Soullier C; Niamkey JT; Ricci JE; Messner-Pellenc P; Brunet X; Schuster I
    J Hypertens; 2016 Aug; 34(8):1615-20. PubMed ID: 27219488
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Predictors of cardiac involvement and survival in patients with primary systemic light-chain amyloidosis: roles of the clinical, chemical, and 3-D speckle tracking echocardiography parameters.
    Lei C; Zhu X; Hsi DH; Wang J; Zuo L; Ta S; Yang Q; Xu L; Zhao X; Wang Y; Sun S; Liu L
    BMC Cardiovasc Disord; 2021 Jan; 21(1):43. PubMed ID: 33478398
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Atrial fibrillation and subtype of atrial fibrillation in cardiac amyloidosis: clinical and echocardiographic features, impact on mortality.
    Sanchis K; Cariou E; Colombat M; Ribes D; Huart A; Cintas P; Fournier P; Rollin A; Carrié D; Galinier M; Maury P; Duparc A; Lairez O;
    Amyloid; 2019 Sep; 26(3):128-138. PubMed ID: 31172799
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.